These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28599943)

  • 1. Correction to Results, Table, and Figure in: Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Chest; 2017 Jun; 151(6):1410. PubMed ID: 28599943
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
    Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
    Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
    Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study of the effects of Aerochamber Plus
    Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
    Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology.
    Taylor G; Warren S; Dwivedi S; Sommerville M; Mello L; Orevillo C; Maes A; Martin UJ; Usmani OS
    Eur J Pharm Sci; 2018 Jan; 111():450-457. PubMed ID: 29055732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
    De Backer W; De Backer J; Vos W; Verlinden I; Van Holsbeke C; Clukers J; Hajian B; Siddiqui S; Jenkins M; Reisner C; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2673-2684. PubMed ID: 30214185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
    Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.
    Doty A; Schroeder J; Vang K; Sommerville M; Taylor M; Flynn B; Lechuga-Ballesteros D; Mack P
    AAPS PharmSciTech; 2018 Feb; 19(2):837-844. PubMed ID: 29019170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.
    D'Urzo AD; Cazzola M; Hanania NA; Buhl R; Maleki-Yazdi MR
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2805-2819. PubMed ID: 30233171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
    Radovanovic D; Mantero M; Sferrazza Papa GF; Valenti V; Aliberti S; Di Marco F; Santus P
    Expert Rev Respir Med; 2016 Oct; 10(10):1045-55. PubMed ID: 27552524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
    Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
    Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
    Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM; Spangenthal S; Kollar C; St Rose E; Reisner C
    Respir Res; 2018 Mar; 19(1):38. PubMed ID: 29506504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
    Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
    Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD.
    Reisner C; Gottschlich G; Fakih F; Koser A; Krainson J; Delacruz L; Arora S; Feldman G; Pudi K; Siddiqui S; Orevillo C; Maes A; St Rose E; Martin U
    Respir Res; 2017 Aug; 18(1):157. PubMed ID: 28821260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial.
    Kerwin E; Wachtel A; Sher L; Nyberg J; Darken P; Siddiqui S; Duncan EA; Reisner C; Dorinsky P
    Respir Med; 2018 Jun; 139():39-47. PubMed ID: 29858000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
    Rabe KF
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):685-698. PubMed ID: 28443352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.